Goldiam International Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/td8zdwhvp6jpdrs88rknwvpn.pdf

Key Takeaways


Lab Grown Diamond Strategy & Margins

Rashesh Bhansali: "We are actually expecting lab grown diamonds to grow very strongly. So, I can say that in FY23, we may look at 25% of the overall business and within three years we expect it to be more than 50% of Goldiam."

FY23 Outlook & Consolidation

Rashesh Bhansali: "And since we have come out from a year of a huge growth, we are looking for a year of consolidation to a modest 5% to 10% growth for the existing year."

Margin Structure & Profitability

Rashesh Bhansali: "If lab grown diamonds become 50% of our business, EBITDA will definitely move close to 25%."

Working Capital & Supply Chain


Competitive Positioning & Market Structure

Anmol Bhansali: "We basically see different retailers playing their strategy as to how they want to introduce lab grown diamonds, it is definitely without a doubt in the US become a category that every retailer needs to have at varying degrees of skill and the Goldiam is striving to be the number one vendor or the number one supplier that can provide an end to end integrated solution for these retailers."

Capital Allocation & Shareholder Returns


Guidance & Commitments

CommitmentSpecificsTimeline
FY23 revenue growth5% to 10% overall growth (year of consolidation)FY23
Lab grown revenue mix25% of overall businessFY23
Lab grown revenue mixMore than 50% of GoldiamWithin three years
EBITDA marginMove close to 25%When lab grown becomes 50% of business
Lab grown capacity additionRs. 10 crores CAPEX, 35% to 40% capacity increase, commercial productionQ1 FY23
Additional lab grown CAPEXRs. 10 crores to 35-40 croresWithin next 12 months
Post-consolidation growth15% to 20% growthAfter FY23 consolidation year
Base business (ex-lab grown) growth5% to 10%Over three years
Shareholder distributionsMinimum 50% of standalone profits via dividends or buybacks (buybacks not forward-looking)Ongoing policy

Key Metrics

MetricQ4 FY22
PAT (full year)₹100 cr+, milestone surpassed for FY22
Revenue growth guidance (FY23)5% to 10%, year of consolidation after high growth
EBITDA margin21%–22%, full year at 22%
Order book₹150 cr+, expected execution in next few months
Lab grown diamond revenue share20% of overall revenue
Lab grown diamond revenue share target (FY23)25% of overall business
Lab grown diamond revenue share target (3 years)more than 50% of Goldiam
E-commerce revenue share15% of business
E-commerce revenue share target (few years)25% of business
ROE (full year)22%, up from 15% in FY21 and 6% in FY18
ROCE (full year)60%, improved from 10.6% in FY18
Cash and cash equivalents₹200 cr as of date
Lab grown diamond capacity addition (May 2022)30% to 35% additional capacity, reaching over 650 polished carats per month
Lab grown diamond ASP premium over natural120% premium over mined diamond jewelry
Natural diamond jewelry ASP$500
Lab grown diamond jewelry ASPover $1,000
Lab grown diamond captive consumptionmore than 85% of growing used for own jewellery orders
US lab grown diamond retail market size$4 bn
Goldiam lab grown diamond revenue (last year)$20 mn
Base business (ex-lab grown) growth guidance (FY23)5% to 10%
Base business growth guidance (3-year CAGR)5% to 10%
Post-FY23 growth guidance15% to 20%
Dividend distribution policy50% minimum of standalone profits, via dividends or buybacks
Power cost per unit₹9, reduced from ₹12–13
Planned additional CAPEX (next 12 months)₹10 cr to ₹35–40 cr for lab grown diamond capacity
Q4 gross margin pressure driverRaw material cost increase due to ALROSA supply constraints and Russian sanctions
OCF after working capital(-)₹15–10 cr, vs ₹50 cr last year, driven by inventory build